Page results
-
Information on safer eating during treatment, for patients with blood cancer.
-
Anticoagulants are medicines that help prevent blood clots. They're given to people at a high risk of getting clots, to reduce their chances of developing serious conditions such as strokes and heart attacks.
-
The diagnostic haematology clinics at UCLH perform comprehensive blood testing, including blood film examination, immunophenotyping and molecular testing.
-
Parenteral Nutrition, also know as PN, is used to feed extremely premature or unwell babies.
-
The UCLH Maternity Voices Partnership (MVP) is a team of women and their families, commissioners and providers (midwives and doctors) working together to review and contribute to the development of local maternity care.
-
This page has been written for patients who have been recommended hormone therapy for prostate cancer. It explains what the treatment involves, describes side-effects you may experience, and how best to cope with them.
-
This booklet is designed for teenagers and young people. It explains what you can expect when you finish your treatment for Hodgkin lymphoma.
-
A guide created by The Red Cell Network with expert patient insight from Elaine Tappin, Miriam Santos Freire and Nneka Smith.
-
How we use your information at UCLH: what you need to know.
-
This page aims to provide information about the syndrome haemophagocytic lymphohistiocytosis (HLH).
File results
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm
-
FOI/2022/0576 - Medications within dermatology